Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · as published 2026-01-23 View official record Methodology

Covered recipient · General Payments record

KEVIN KALINSKY

Allopathic & Osteopathic Physicians Internal Medicine Medical Oncology

NPI
1669430310
CMS profile
166098
Location
NEW YORK, NY

General Payments · PY2018–2024

$336,237.80

  • Reported across 327 records
  • CMS publication 2026-01-23

Latest program year · PY2024

$18,780.35

13 records · 0 disputed

Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.

How these totals are calculated
  • The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
  • Methodology & Data — sourcing, labeling, and limitations.

By nature of payment

PY2024 · sorted by reported total

By paying entity

PY2024 · sorted by reported total

Paying entityAmountRecords
F. Hoffmann-La Roche AG $4,954.45 2
Gilead Sciences, Inc. $4,020.00 1
Genentech, Inc. $3,351.85 2
PFIZER INC. $2,520.00 3
Merck Sharp & Dohme Corporation $2,180.00 2
AstraZeneca UK Limited $1,027.50 1
Acerta Pharma LLC $685.00 1
Eli Lilly and Company $41.55 1

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2018 $146,588.82 138
PY2019 $82,952.07 102
PY2020 $24,525.00 10
PY2021 $20,616.00 12
PY2022 $24,500.49 21
PY2023 $18,275.07 31
PY2024 $18,780.35 13

Payment records · PY2024 (13)

Sorted by paying entity, then date · as published by CMS

Program year 2024 201820192020202120222023 Record-level detail is published for PY2024; earlier years are summarised in “By program year”.
Paying entity Amount Date Nature of payment Dispute status Published Record ID Source
AstraZeneca Pharmaceuticals LP $685.00 05/10/2024 Consulting Fee Undisputed 01/23/2026 1105603286 CMS
AstraZeneca UK Limited $1,027.50 10/17/2024 Consulting Fee Undisputed 01/23/2026 1093941036 CMS
Eli Lilly and Company $41.55 12/10/2024 Food and Beverage Undisputed 01/23/2026 1135111606 CMS
F. Hoffmann-La Roche AG $14.45 05/30/2024 Food and Beverage Undisputed 01/23/2026 1133047854 CMS
F. Hoffmann-La Roche AG $4,940.00 09/16/2024 Consulting Fee Undisputed 01/23/2026 1133047858 CMS
Genentech, Inc. $3,280.00 12/09/2024 Consulting Fee Undisputed 01/23/2026 1133047862 CMS
Genentech, Inc. $71.85 12/09/2024 Food and Beverage Undisputed 01/23/2026 1133047866 CMS
Gilead Sciences, Inc. $4,020.00 03/26/2024 Consulting Fee Undisputed 01/23/2026 1133600063 CMS
Merck Sharp & Dohme LLC $1,090.00 06/19/2024 Consulting Fee Undisputed 01/23/2026 1141714912 CMS
Merck Sharp & Dohme LLC $1,090.00 12/16/2024 Consulting Fee Undisputed 01/23/2026 1141874514 CMS
PFIZER INC. $1,260.00 07/03/2024 Consulting Fee Undisputed 01/23/2026 1131906519 CMS
PFIZER INC. $630.00 10/03/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program Undisputed 01/23/2026 1130891726 CMS
PFIZER INC. $630.00 12/09/2024 Consulting Fee Undisputed 01/23/2026 1131228747 CMS

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-01-23
Program years on this page
2018, 2019, 2020, 2021, 2022, 2023, 2024
Source files
Dataset page · Bulk file · PY2018 , PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
Generated from
OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.